ORPHAN AND ULTRA-ORPHAN TECHNOLOGIES: EUROPEAN AND AUSTRALIAN PAYER PERCEPTIONS

被引：0
|
作者：
Hogue, S. [1 ]
Brogan, A. P. [1 ]
Croft, E. [2 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] RTI Hlth Solut, Manchester, Lancs, England
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2027
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY127
引用
下载
收藏
页码：A681 / A681
页数：1
相关论文
共 50 条
  • [41] Single-Center Experience with Intimal Sarcoma, an Ultra-Orphan, Commonly Fatal Mesenchymal Malignancy
    Van Dievel, Julie
    Sciot, Raf
    Delcroix, Marion
    Vandeweyer, Raf O.
    Debiec-Rychter, Maria
    Dewaele, Barbara
    Cornillie, Jasmien
    Van Cann, Thomas
    Meyns, Bart
    Schoffski, Patrick
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (06) : 353 - 359
  • [42] US COMMERCIAL PAYER AND RARE DISEASE PATIENT STAKEHOLDER PERCEPTIONS OF VALUE OF ORPHAN DRUGS
    Narayanan, S.
    VALUE IN HEALTH, 2022, 25 (12) : S298 - S298
  • [43] IS ULTRA-ORPHAN DISEASE TREATMENT ACCESS EQUITABLE IN THE UK? COMPARISON BETWEEN SMC AND NICE HST GUIDANCE
    Tang, M.
    Samuels, E.
    VALUE IN HEALTH, 2022, 25 (01) : S186 - S186
  • [44] Single-center experience with intimal sarcoma, an ultra-orphan, commonly fatal mesenchymal malignancy.
    Van Dievel, Julie
    Sciot, Raf
    Delcroix, Marion
    Vandeweyer, Raf
    Debiec-Rychter, Maria
    Dewaele, Barbara
    Cornillie, Jasrnien
    Van Cann, Thomas
    Meyns, Bart
    Schoffski, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF ULTRA-ORPHAN THERAPIES: LESSON LEARNED FROM PUBLISHED HTAS AND STUDIES
    Aggarwal, S.
    Topaloglu, H.
    Kumar, S.
    VALUE IN HEALTH, 2015, 18 (03) : A8 - A8
  • [46] AUSTRALIAN IVF - ORPHAN EMBRYOS
    SELLAR, J
    NATURE, 1984, 309 (5971) : 738 - 738
  • [47] Needles in a haystack: ultra-orphan invasive fungal infections reported in FungiScope® - Global registry for emerging fungal infections
    Salmanton-Garcia, J.
    Koehler, P.
    Mellinghoff, S. C.
    Wisplinghoff, H.
    Cornely, O. A.
    Seidel, D.
    MYCOSES, 2020, 63 : 17 - 17
  • [48] ASSESSMENT OF COMMERCIAL AND MARKET ACCESS POTENTIAL AND CONSIDERATIONS FOR AN ULTRA-ORPHAN DRUG FOR RENAL DISEASE IN EU5
    Smith, L. A.
    Edathodu, A.
    Samuel, J. J.
    Mukku, S. R.
    VALUE IN HEALTH, 2018, 21 : S264 - S264
  • [49] Defining orphan conditions in the context of the European orphan regulation: challenges and evolution
    O'Connor, Daniel J.
    Sheean, Maria E.
    Hofer, Matthias P.
    Tsigkos, Stelios
    Mariz, Segundo
    Fregonese, Laura
    Larsson, Kristina
    Hivert, Virginie
    Westermark, Kerstin
    Naumann-Winter, Frauke
    Stoyanova-Beninska, Violeta
    Barisic, Ingeborg
    Capovilla, Giuseppe
    Magrelli, Armando
    Sepodes, Bruno
    NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (07) : 479 - 480
  • [50] Defining orphan conditions in the context of the European orphan regulation: challenges and evolution
    Daniel J. O’Connor
    Maria E. Sheean
    Matthias P. Hofer
    Stelios Tsigkos
    Segundo Mariz
    Laura Fregonese
    Kristina Larsson
    Virginie Hivert
    Kerstin Westermark
    Frauke Naumann-Winter
    Violeta Stoyanova-Beninska
    Ingeborg Barišić
    Giuseppe Capovilla
    Armando Magrelli
    Bruno Sepodes
    Nature Reviews Drug Discovery, 2019, 18 : 479 - 480
12345